Race Oncology Limited announced changes to the Board and Management team structure, to ensure the company and its lead asset, bisantrene, are suitably positioned for clinical success. Effective immediately, Dr. Peter Smith will step into the role of Executive Director, taking over from Damian Clarke-Bruce, who has tendered his resignation. Non-Executive Director, Dr. John Cullity has advised his intention to retire from the Race Board, following a long and productive tenure.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.455 AUD | -3.64% | -7.03% | +73.21% |
Mar. 26 | Race Oncology Obtains Certificate of Analysis for RC220; Shares Up Almost 6% | MT |
Mar. 18 | Race Oncology Limited(ASX:RAC) dropped from S&P/ASX All Ordinaries Index | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+73.21% | 168M | |
+10.98% | 115B | |
+12.65% | 106B | |
-4.42% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-11.29% | 17.56B | |
-39.36% | 17.32B | |
+7.35% | 14.03B | |
+33.04% | 12.13B |
- Stock Market
- Equities
- RAC Stock
- News Race Oncology Limited
- Race Oncology Limited Announces Board Changes